You are here: Industry Insights > Sankyo

News List

Daiichi Sankyo Presents Positive Results from LIXIANA Study americanpharmaceuticalreview
September 05, 2019
Daiichi Sankyo announced results from ENTRUST-AF PCI, the first large randomized study to evaluate the efficacy and safety of once-daily edoxaban (known by the brand name LIXIANA®▼) plus a P2Y12 inhibitor...
Daiichi Sankyo Reports Positive Initial Results from Bempedoic Acid / Ezetimibe Study americanpharmaceuticalreview
September 03, 2019
Daiichi Sankyo Europe GMbH announced positive initial results from the 12-week Phase 2 bempedoic acid / ezetimibe fixed dose combination (FDC) tablet study (also known as Study 058).
Daiichi Sankyo Names Chief People Officer contractpharma
August 26, 2019
Simon King will human resources across all U.S. divisions.
Results of the Pivotal Phase 3 Study of the Bempedoic Acid / Ezetimibe Combination Tablet Published in the European Journal of Preventative Cardiology Demonstrated Significant LDL-C Lowering b3cnewswire
August 01, 2019
Daiichi Sankyo Europe GmbH (hereafter, ‘Daiichi Sankyo’)announced that results from the 12-week, pivotal Phase 3 bempedoic acid / ezetimibe FDC tablet study...
Daiichi Sankyo Provides Update on FDA Review of Quizartinib for the Treatment of Patients with Relapsed/Refractory FLT3-ITD AML drugs
June 25, 2019
Daiichi Sankyo Provides Update on FDA Review of Quizartinib for the Treatment of Patients with Relapsed/Refractory FLT3-ITD AML.
Daiichi Sankyo Announces Outcome of FDA Oncologic Drugs Advisory Committee Meeting to Review FLT3 Inhibitor Quizartinib for the Treatment of Patients with Relapsed/Refractory FLT3-ITD AML drugs
May 20, 2019
Daiichi Sankyo Announces Outcome of FDA Oncologic Drugs Advisory Committee Meeting to Review FLT3 Inhibitor Quizartinib for the Treatment of Patients with Relapsed/Refractory FLT3-ITD AML.
Daiichi Sankyo Provides Update on Ongoing FDA Review for Quizartinib for Treatment of Patients with Relapsed/Refractory FLT3-ITD AML drugs
April 17, 2019
Daiichi Sankyo Provides Update on Ongoing FDA Review for Quizartinib for Treatment of Patients with Relapsed/Refractory FLT3-ITD AML.
Daiichi Sankyo to develop new inflammatory disease drugs pharmaceutical-technology
June 01, 2018
Daiichi Sankyo has formed a new consortium focused on research and discovery of medicines over a period of five years to treat intractable immune-mediated inflammatory diseases.